从对化学抗原受体T细胞免疫疗法在癌症中的单细胞分析中获得的见解

Lu Tang1,2,3, Zhong-Pei Huang1,2,3, Heng Mei4,5,6,7

  • 1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Military Medical Research
|November 8, 2023
PubMed
概括

单细胞测序揭示了对仿真抗原受体 (CAR) -T细胞治疗失败和成功的见解. 这项技术有助于优化CAR-T细胞设计和制造,以改善血液恶性瘤患者的治疗结果.